Table 3 Diastolic blood pressure level and intra-individual visit-to-visit variability in the three treatment groups during the BP measurement phase

From: Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial

    

Difference (95% CI)

P-value

 

Benidipine plus ARB (n=1026)

Benidipine plus BB (n=996)

Benidipine plus TD (n=991)

ARB/BB

ARB/TD

BB/TD

ARB/BB

ARB/TD

BB/TD

Mean, mm Hg

78.1±7.6

78.0±7.8

78.4±8.0

0.15

−0.30

−0.44

0.909

0.668

0.421

    

−0.53–0.82

−0.98–0.38

−1.14–0.26

   

Maximum, mm Hg

87.2±8.9

87.2±9.5

87.2±9.1

−0.07

−0.04

0.03

0.984

0.996

0.996

    

−0.88–0.74

−0.82–0.75

−0.79–0.86

   

Minimum, mm Hg

69.3±9.1

69.0±9.2

69.8±9.2

0.26

−0.51

−0.77

0.799

0.424

0.149

    

−0.54–1.07

−1.31–0.29

−1.59–0.04

   

Maximum–minimum, mm Hg

17.9±8.5

18.2±8.9

17.4±8.4

0.33

0.47

0.81

0.664

0.431

0.096

    

−1.10–0.43

−0.27–1.22

0.04–1.57

   

Visit-to-visit variability

 s.d., mm Hg

6.95±3.23

7.06±3.36

6.70±3.08

−0.11

0.26

0.37

0.727

0.167

0.030

    

−0.40–0.18

−0.02–0.54

0.08–0.66

   

 CV, %

9.02±4.36

9.18±4.50

8.66±4.14

−0.15

0.37

0.52

0.711

0.140

0.022

    

−0.54–0.24

−0.01–0.74

0.14–0.90

   
  1. Abbreviations: ARB, angiotensin receptor blocker; BB, β-blocker; CI, confidence interval; CV, coefficient of variance; TD, thiazide diuretic.
  2. Data are shown as the mean±s.d. The following inclusion criteria were adopted for the post hoc analysis of the COPE trial: (1) subjects who did not develop any cardiovascular events within 18 months after randomization, and (2) subjects who had measured their clinic BP at least three times over at least 18 months to evaluate intra-individual visit-to-visit BP variability during the 36-month BP measurement phase. Differences in the mean, maximum, minimum, maximum–minimum, s.d. and CV of BP values between two treatment groups (ARB/BB, ARB/TD or BB/TD) were analyzed using Tukey’s multiple comparison test.